Tempus AI, Inc. (NASDAQ:TEM) Director David R. Epstein Sells 990 Shares

Tempus AI, Inc. (NASDAQ:TEM) Director David R. Epstein sold 990 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $46.83, for a total transaction of $46,361.70. Following the completion of the sale, the director now directly owns 26,284 shares of the company’s stock, valued at approximately $1,230,879.72. This trade represents a 3.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Tempus AI Stock Performance

Shares of Tempus AI stock opened at $48.03 on Thursday. Tempus AI, Inc. has a 52-week low of $22.89 and a 52-week high of $91.45. The firm’s 50 day moving average price is $55.86 and its 200-day moving average price is $51.48. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Needham & Company LLC boosted their price target on Tempus AI from $56.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. TD Cowen reiterated a “buy” rating and issued a $74.00 target price (up from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Morgan Stanley raised their price target on Tempus AI from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, March 6th. JPMorgan Chase & Co. lowered shares of Tempus AI from an “overweight” rating to a “neutral” rating and upped their price objective for the stock from $50.00 to $55.00 in a research note on Tuesday, February 25th. Finally, Loop Capital cut their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $61.18.

Hedge Funds Weigh In On Tempus AI

Large investors have recently made changes to their positions in the business. Kovitz Investment Group Partners LLC purchased a new position in Tempus AI during the 3rd quarter worth $1,367,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Tempus AI during the fourth quarter valued at about $1,091,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Tempus AI in the 4th quarter valued at approximately $178,000. Captrust Financial Advisors acquired a new stake in Tempus AI in the 3rd quarter worth approximately $2,726,000. Finally, abrdn plc purchased a new stake in Tempus AI during the 4th quarter worth approximately $2,784,000. 24.22% of the stock is owned by institutional investors and hedge funds.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.